Sanofi reported "positive" results from the clinical trial assessing Dupixent in adults and adolescents with uncontrolled moderate-to-severe atopic hand and foot dermatitis were presented today. The trial, which the company said is "the first evaluating a biologic for this difficult-to-treat population," met its primary and key secondary endpoints. The results were featured in a late-breaking session, one of more than 20 Dupixent scientific presentations, at the American Academy of Dermatology, or AAD, 2023 Annual Meeting. At 16 weeks, patients treated with Dupixent experienced the following: 40% achieved clear or almost clear skin on hands and feet compared to 17% with placebo, the primary endpoint; 52% saw a clinically meaningful reduction in itch on hands and feet compared to 14% with placebo, the key secondary endpoint; 69% average reduction in signs of hand and foot lesions from baseline compared to 31% with placebo; 75% average improvement in hand eczema disease severity from baseline compared to 40% with placebo. There were significant improvements in measures of hand and foot skin pain, sleep and hand eczema-related quality of life.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SNY:
